Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label BI 3011441 trial in Japanese patients with NRAS/KRAS-mutant advanced refractory solid tumors
jRCT2031200249Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 3011441 in Nonhematologic neoplasms (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicities in the MTD evaluation period. Started Mar 2021; status: active, not recruiting.
02
Drugs
BI 3011441
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200249.